UCSF scientists found a way to predict Alzheimer’s disease up to seven years before symptoms appear by analyzing patient records with machine learning. Conditions that most influenced prediction of Alzheimer’s were high cholesterol and, for women, osteoporosis.
Medication abortion can be delivered safely and effectively through telemedicine, according to new research that comes as the U.S. Supreme Court is about to hear a case that could severely restrict access to one of the two pills that are used to induce abortions.
Bruce Ovbiagele, MD, MAS, FAAN, has been chosen by the American Brain Foundation (ABF) to receive its annual Scientific Breakthrough Award. He is honored for his work in health equity and inclusion, improving stroke outcomes for underserved and vulnerable populations.
In a first, scientists at UCSF and Stanford identified genetic variants that predict whether a patient is likely to respond to treatment for preterm birth. Screening for mutations could allow doctors to target medications to those most likely to benefit. No medication is currently available in the U.S. to treat preterm birth.
Young Black and Hispanic women with multiple sclerosis fare worse than young white women with the disease. Minority women were more likely to have more advanced disease and faced greater challenges in pregnancy.
Early identification of posterior cortical atrophy (PCA) may have important implications for Alzheimer’s treatment. PCA patients struggle with visual impairments like judging distances, distinguishing between moving and stationary objects and completing tasks like writing and retrieving a dropped item.
The Danaher-IGI Beacon for CRISPR Cures center will use genome editing to address potentially hundreds of diseases, including rare genetic disorders that have no cure, to ensure treatments can be developed and brought to patients more quickly and efficiently.
Researchers at UCSF and UC Berkeley are investigating the impact of pre- and post-natal exposures to tobacco smoke on the survival rate of children with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
Hematologists and oncologists from around the world will present new research and clinical findings at the American Society of Hematology’s (ASH) 65th Annual Meeting and Exposition. This year’s meeting will be held in San Diego from Dec. 8-12, 2023.